---
title: "Astrazeneca: Phase III clinical trial results indicate that the blockbuster immunotherapy drug Imfin"
description: "Astrazeneca: Phase III clinical trial results indicate that the blockbuster immunotherapy drug Imfinzi (durvalumab) showed improvement in the primary endpoint"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242714610.md"
published_at: "2025-06-01T12:29:22.000Z"
---

# Astrazeneca: Phase III clinical trial results indicate that the blockbuster immunotherapy drug Imfin

> Astrazeneca: Phase III clinical trial results indicate that the blockbuster immunotherapy drug Imfinzi (durvalumab) showed improvement in the primary endpoint

Astrazeneca: Results from the Phase III clinical trial indicate that the blockbuster immunotherapy drug Imfinzi (durvalumab) showed improvement in the primary endpoint

### Related Stocks

- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Trump Strikes Again: AstraZeneca's Surprise Drug Deal Could Shake Big Pharma's Global Pricing Power | AstraZeneca has reached a drug-pricing deal with President Trump to reduce Medicaid drug prices, potentially reshaping B | [Link](https://longbridge.com/en/news/260941568.md) |
| ANALYSIS-AstraZeneca's US listing may pull other firms from London in its wake | AstraZeneca's decision to upgrade its U.S. listing while retaining its London presence may influence other UK firms to c | [Link](https://longbridge.com/en/news/259563996.md) |
| Short Interest in Schneider Electric SE (OTCMKTS:SBGSY) Drops By 16.8% | Schneider Electric SE (OTCMKTS:SBGSY) experienced a 16.8% decrease in short interest in January, with 197,858 shares sho | [Link](https://longbridge.com/en/news/276071356.md) |
| Bernstein Flags Gross Margin Impact of EssilorLuxottica's Smart Glasses Business Boom | Bernstein Flags Gross Margin Impact of EssilorLuxottica's Smart Glasses Business Boom | [Link](https://longbridge.com/en/news/276044799.md) |
| What to Expect from Palo Alto Networks's Earnings | Palo Alto Networks (NASDAQ:PANW) is set to release its quarterly earnings report on February 17, 2026, with analysts exp | [Link](https://longbridge.com/en/news/276061399.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.